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End-stage liver diseases are an increasing health burden, and liver 
transplantations are currently the only curative treatment option. Due 
to a lack of donor livers, alternative treatments are urgently needed. 
Human liver organoids are very promising for regenerative medicine; 
however, organoids are currently cultured in Matrigel, which is extracted 
from the extracellular matrix of the Engelbreth-Holm-Swarm mouse 
sarcoma. Matrigel is poorly defined, suffers from high batch-to-batch 
variability and is of xenogeneic origin, which limits the clinical application 
of organoids. Here, a novel hydrogel based on polyisocyanopeptides 
(PIC) and laminin-111 is described for human liver organoid cultures. PIC 
is a synthetic polymer that can form a hydrogel with thermosensitive 
properties, making it easy to handle and very attractive for clinical 
applications. Organoids in an optimized PIC hydrogel proliferate at 
rates comparable to those observed with Matrigel; proliferation rates are 
stiffness-dependent, with lower stiffnesses being optimal for organoid 
proliferation. Moreover, organoids can be efficiently differentiated toward 
a hepatocyte-like phenotype with key liver functions. This proliferation and 
differentiation potential maintain over at least 14 passages. The results 
indicate that PIC is very promising for human liver organoid culture and 
has the potential to be used in a variety of clinical applications including 
cell therapy and tissue engineering.
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1. Introduction
The liver is the largest internal organ in 
the body and is responsible for crucial met-
abolic functions. Upon acute damage, the 
liver has a great regenerative capacity and 
can restore up to 70% of its mass.[1] How-
ever, injury caused by chronic diseases 
such as viral infections or alcoholic fatty 
liver disease lead to a gradual decrease in 
liver function, eventually resulting in end-
stage liver disease.[2] For end-stage liver 
disease, the only curative treatment option 
is organ transplantation.[3] Unfortunately, 
the demand for transplantable donor 
livers far exceeds availability, resulting 
in approximately 20% of patients dying 
while on the waitlist.[4] In addition, the 
experience of waiting for a donor organ 
is a great burden to the patient and the 
stress of not knowing if a donor organ will 
become available in time can negatively 
impact prognosis.[5] Alternatives for donor 
livers are thus urgently needed.[6]
Liver organoids hold great promise for 
regenerative approaches, for example, cell 
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therapy or as cellular building blocks for liver tissue engi-
neering.[7] Organoids are 3D miniature versions of their organ of 
origin, which contain most, if not all, cell types that are present in 
vivo.[8] Human liver organoids can be initiated from a variety of 
cells, including embryonic stem cells,[9] induced pluripotent stem 
cells (PSCs),[10] multipotent adult tissue-resident stem cells,[11,12] 
and primary  hepatocytes.[13] In this paper, we focus on organoids 
established from leucine-rich repeat-containing G-protein cou-
pled receptor 5 positive (LGR5+) adult liver stem cells. These 
organoids can be expanded infinitely in culture, remain geneti-
cally stable, and can be differentiated into the hepatocyte[11,12] or 
cholangiocyte[14] lineages; as such, they reflect important func-
tional and structural aspects of the liver. Transplantation experi-
ments have shown that organoids were able to engraft into the 
damaged parenchyma of mice and rats, where they became 
functional hepatocytes, although the repopulation efficiency 
remained low.[11,12,15] Another benefit is the ability to genetically 
modify these organoids in vitro using the CRISPR/Cas system, 
and in theory, enable the correction of relatively simple genetic 
defects of a patient prior to autologous cell transplantation.[16]
The current gold standard for organoid culture is critically 
dependent on the use of Matrigel as a 3D matrix. Matrigel is 
a gelatinous protein mixture extracted from the extracellular 
matrix (ECM) of the Engelbreth-Holm-Swarm mouse sarcoma, 
which is propagated in mice.[17] Matrigel is widely used because 
it is extremely bioactive and therefore supports proliferation of a 
wide variety of organoid types.[18] Organoids cultured in Matrigel, 
however, are unsuitable for clinical use due to the murine tumor 
origin of Matrigel. Another disadvantage of Matrigel is very 
high (up to 50%) batch-to-batch variations, which may influence 
reproducibility of organoid experiments.[19]
In this paper, we sought to develop a synthetic, defined and 
easy-to-handle Matrigel alternative for the expansion and dif-
ferentiation of human liver organoids. In 2016, Gjorevski et al. 
published the first landmark paper in the field of synthetic 
hydrogels for organoid culture.[20] Murine intestinal organoid 
formation and differentiation was successfully achieved in 
an enzymatically-crosslinked polyethylene glycol (PEG)-based 
hydrogel when modified with laminin or Arg-Gly-Asp (RGD) 
peptides. This group recently published a preprint on bioRxiv, 
in which they applied the same PEG-based hydrogel for the cul-
ture of murine and human liver organoids.[21] Moreover, in 2018, 
Broguiere et  al. published a defined (although not synthetic) 
hydrogel based on a combination of a thrombin-crosslinked 
fibrin gel, nanocellulose and laminin-111/entactin complex.[22] 
The gel was as efficient as Matrigel for the expansion and differ-
entiation of murine intestinal organoids and also seemed to be 
applicable for the expansion of human organoids from a variety 
of different organs. However, both PEG and fibrin-based hydro-
gels must be chemically or enzymatically cross-linked to achieve 
gelation, which complicates the retrieval of organoids from the 
hydrogel and may be a disadvantage for certain applications.
In this study, we used hydrogels based on polyisocyanopep-
tides (PIC), a synthetic nonimmunogenic material, for the 
expansion and differentiation of human liver organoids.[23] 
Because PIC-based hydrogels exhibit thermoreversible gelation, 
they are convenient to work with, provide gentle conditions for 
organoids during passaging and have a unique range of applica-
tions, such as the use of the hydrogel for bioprinting without a 
necessity for enzymatic or light-induced cross-linking.[24] PIC is 
a free-flowing liquid below 16 °C;[25] when the temperature rises 
above 16 °C, the liquid becomes a viscous hydrogel within min-
utes. This flexible behavior facilitates simple cell recovery pro-
tocols that merely rely on changing the temperature. It is also 
possible to modify the PIC backbone with a variety of desired 
molecules and bioactive epitopes.[26] Most importantly, PIC is a 
bioinert material and has already been applied by others in vivo 
without evoking any adverse immune response.[27] We therefore 
expect that culturing organoids in a PIC hydrogel will enable 
their use for organoid-based clinical applications such as cell 
therapy and tissue engineering approaches.
2. Results and Discussion
2.1. An Optimized PIC Hydrogel Supports Liver Organoid 
Expansion
We first developed a PIC hydrogel that supports organoid forma-
tion and proliferation. PIC itself does not contain any bioactive 
components to support cell attachment or induce proliferation. 
Accordingly, we observed marginal organoid formation, with little 
to no proliferation when single organoid cells were seeded in 
plain PIC and cultured for 7 days in organoid expansion medium 
(EM) (Figure 1a). To stimulate proliferative pathways involved in 
cell attachment to the ECM, we tested a PIC hydrogel that con-
tained covalently-attached RGD sequences, which can be recog-
nized by cellular integrins.[20] However, the incorporation of RGD 
motifs in PIC was not sufficient to induce organoid proliferation 
(Figure 1a). Our findings contrast with the recently published pre-
print by Sorrentino et  al., where the addition of RGD motifs to 
a PEG hydrogel seemed sufficient for human liver organoid cul-
ture; our dissimilar results may be explained by a difference in 
RGD concentrations. In our commercially purchased hydrogel, 
RGD peptides are covalently coupled to the PIC at a concentration 
of ≈0.2 mm, whereas concentrations of 1–2 mm have been used in 
earlier publications.[21] We continued to add 3 mg mL−1 laminin-
entactin complex (LEC) to the plain PIC gel, which resulted 
in efficient organoid formation and proliferation that seemed 
comparable to the Matrigel controls (Figure 1a). LEC is the main 
component of Matrigel and has previously been shown to promote 
formation and proliferation of murine intestinal organoids.[22]
We then examined the effects of the mechanical properties of 
PIC hydrogels on liver organoid proliferation. We used PIC at two 
different molecular weights, 1 kDa PIC (1k PIC) and 5 kDa PIC 
(5k PIC), and modulated the hydrogels by varying PIC concen-
trations, resulting in a higher stiffness and lower porosity with 
increasing concentrations. Light microscopy pictures and Alamar 
blue assays (ABAs) confirmed that lower PIC concentrations led 
to a significantly increased organoid proliferation (Figure 1b).
After determining the optimal PIC concentration 
(1 mg mL−1), we continued to optimize the concentration of 
LEC in PIC. In both the 1k PIC and 5k PIC hydrogel backbones, 
we observed a concentration-dependent increase in organoid 
proliferation (Figure  1c), with highest proliferation rates at 
3 mg mL−1 LEC in a 1k PIC hydrogel (Figure 1d,e).
Taken together, a 1k PIC hydrogel at a concentration of 
1 mg mL−1 PIC, supplemented with 3 mg mL−1 LEC, provided 
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an environment that optimally supported organoid formation 
and proliferation with an efficiency comparable to Matrigel.
2.2. Soft PIC Hydrogels Enhance Organoid Expansion
To gain more insights into the different PIC hydrogels, we 
analyzed their mechanical properties. As the gelation of both 
Matrigel and PIC hydrogels is temperature-dependent, we placed 
the different hydrogel premixes on a temperature-controlled 
plate and followed their gelation in time. The plate was heated 
from 4 to 37 °C at a speed of +7 °C min−1 and then maintained 
at a temperature of 37  °C for 10 min. Our analysis of storage 
modulus G′ showed that for all premixes, gelation started during 
the heating period and reached a plateau after 10 min at 37 °C 
(Figure 2a). We observed that the stiffness of the 5k PIC (≈83 Pa) 
was comparable to that of Matrigel (≈71 Pa), whereas the stiffness 
of all other PIC hydrogels (with and without LEC) was lower. The 
5k PIC hydrogels demonstrated a higher stiffness (≈83 Pa) com-
pared to 1k PIC hydrogels (≈18  Pa) of the same concentration 
Adv. Funct. Mater. 2020, 2000893
Figure 1. An optimized PIC hydrogel supports liver organoid expansion. Single organoid cells were seeded at day 0 and cultured in human organoid expan-
sion medium (EM) supplemented with the Rho kinase inhibitor Y-27632 for 14 days. Four different donors were analyzed in independent experiments 
(N = 4). a) Light microscopy images of organoids at day 7 after single cell seeding. Organoids did not proliferate in PIC-plain and PIC-RGD, but showed a 
morphology comparable to Matrigel in PIC supplemented with 3 mg mL−1 LEC (PIC-LEC). b) Lower concentrations of PIC improve organoid proliferation. 
c) Light microscopy pictures reveal a dose-dependent effect of LEC on organoid proliferation. Quantification of organoid proliferation in d) 5k PIC and e) 1k 
PIC. Organoids from five different donors were cultured in Matrigel or PIC with different concentrations of LEC. Relative cell numbers were determined by an 
Alamar blue assay every 2–3 days and cell expansion relative to day 0 was calculated. Each dot represents the mean of the four donors with standard deviation.
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and the addition of LEC resulted in a decreased stiffness for 
both the 1k (≈12 Pa) and 5k (≈38 Pa) PIC hydrogels (Figure 2a,b), 
which was most likely caused by sterical interference of PIC 
network formation by the large laminin molecules. By con-
trast, increasing LEC concentrations did not significantly affect 
hydrogel stiffnesses of the same PIC concentration, suggesting 
that the LEC concentration-dependent organoid proliferation was 
caused by biological rather than mechanical effects (unpublished 
data). As such, the softest PIC hydrogel (1k PIC hydrogel at a 
concentration of 1 mg mL−1 PIC, supplemented with 3 mg mL−1  
LEC) best supported liver organoid expansion. This corresponds 
with our observations that organoids proliferate better in 70% 
Matrigel (diluted with culture media and thus, softer) compared 
to 100% Matrigel (unpublished data). Remarkably, Sorrentino 
et al. observed that, for their PEG hydrogels, a much higher stiff-
ness of 1.3 kPa optimally supported colony formation of human 
liver organoids, whereas a lower stiffness of 0.3 kPa was much 
less efficient.[21] The authors, however, did not quantify prolifera-
tion of the liver organoids in their various hydrogels.
For serial passaging and long-term expansion of organoids 
in 3D culture, the thermoreversible character of PIC hydrogels 
is one of the most significant advantages over other hydrogels. 
Using a rheometer, we compared the thermoreversible char-
acter of PIC hydrogels with Matrigel through a controlled tem-
perature change. We first heated the hydrogel premixes from 
4 to 37  °C, allowing them to form a hydrogel. Subsequently, 
we cooled the hydrogels down to 4 °C at a speed of 7 °C min−1 
and then kept the samples at 4  °C for another 10  min to see 
whether they would become liquid again. Our results show that 
the optimized PIC-LEC hydrogel promoted a faster gel/sol tran-
sition than Matrigel (Figure 2c). After approximately 6 min of 
heating, the PIC-LEC hydrogels turned into a gel, which imme-
diately turned into solution again upon cooling (Figure 2c). In 
contrast, Matrigel still had a stiffness of ≈50 Pa after a 15 min 
cooling period (Figure  2c). This corresponds with our obser-
vations that PIC hydrogels are more easily manipulated and 
thereby easier to handle during organoid passaging, giving 
them a major advantage over Matrigel.
We also characterized the dynamic properties of PIC hydro-
gels after gelation, since this may influence organoid shape and 
size. We investigated the modulus change of the hydrogels in a 
frequency range from 10 to 0.1 rad s−1. Both Matrigel and PIC 
Adv. Funct. Mater. 2020, 2000893
Figure 2. Soft PIC hydrogels enhance organoid expansion. Mechanical properties of Matrigel and PIC hydrogels measured at constant frequency 
(1 rad s−1) and strain (1%). a) Time trace of storage modulus G′ showing hydrogel gelation with the temperature raising from 4 to 37 °C (+7 °C min−1) 
and holding at 37 °C. For all conditions, the starting modulus at time = 0 min were much lower because all the samples were liquid at 4 °C; the modulus 
almost reached plateau at time = 6 min when the temperature was held at 37 °C (N = 3). b) Stiffness of hydrogels showing the storage modulus G′ 
of Matrigel and PIC hydrogels after 10 min incubation at 37 °C (N = 3). c) Time trace of storage modulus G′ and loss modulus G′′ of Matrigel and 
PIC-LEC hydrogels through a heating and cooling cycle. At time = 0 min, G′ and G′′ were close to each other in all three conditions showing a liquid 
state; at time = 5 min, G′ reached a peak higher than G′′ after heating from 4 to 37 °C (+7 °C min−1); during time = 5–10 min, all gels remained plateaued 
when the temperature was held at 37 °C; after time = 15 min, both PIC hydrogels showed a sharp decrease of G′ when the cooling cycle started from 
37 to 4 °C (−7 °C min−1), and G′ of both PIC hydrogels dropped to less than 1 Pa after being held at 4 °C for 10 min. However, G′ of Matrigel was still 
higher than 50 Pa after cooling for 15 min (N = 2).
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hydrogels were stable in the measured frequency range and 
behaved as a viscoelastic solid (Figure S1, Supporting Informa-
tion). Interestingly, the addition of LEC did not influence the 
dynamic properties of the PIC hydrogels, indicating that the 
dynamic character of the PIC-LEC hydrogels did not play a key 
role in supporting organoid expansion.
2.3. Organoids in PIC Retain a Stem/Progenitor Phenotype 
and Are Highly Proliferative
To further characterize liver organoids in the optimized PIC-
LEC hydrogel, we seeded single organoid cells in EM conditions 
and cultured them for 14 days. Single organoid cells seeded in 
Matrigel were used as a control. Immunofluorescent analysis 
showed that the cells in all hydrogels retained an epithelial 
E-cadherin (ECAD)-positive phenotype and were highly prolif-
erative (Figure 3a).
To further interrogate this proliferative phenotype, we 
performed mRNA sequencing on organoids from two dif-
ferent donors that were cultured in 1k PIC-LEC, 5k PIC-LEC, 
or Matrigel for 14 days. A Pearson’s correlation test showed 
that all hydrogel conditions (Matrigel, 1k PIC, and 5k PIC) 
displayed a similar correlation coefficient for each donor 
(Figure  3b). We then analyzed the expression of a few well-
known liver stem/progenitor cell markers (LGR5, SOX9, 
Adv. Funct. Mater. 2020, 2000893
Figure 3. Organoids in PIC retain a stem/progenitor phenotype and are highly proliferative. Single organoid cells were seeded at day 0 and organoids were 
expanded in the different hydrogels for 14 days. Three different donors were analyzed in independent experiments (N = 3). a) Immunofluorescent analysis 
of paraffin-embedded organoids confirmed that the organoids in all gels have an epithelial progenitor phenotype and are highly proliferative. Human liver 
tissue was used as a control. Whole transcriptome sequencing analysis of organoids from two independent donors at day 7 of expansion in Matrigel, 1k 
PIC-LEC, and 5k PIC-LEC (N = 2). b) Pearson correlation map of the organoids in different hydrogels. Note that the correlation of cultured organoids is 
more than 99%. c) Heatmap of markers for stem/progenitor cells, epithelial cells, and mature hepatocytes selected from the mRNA sequencing data.
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EPCAM, PROM1, AXIN2), proliferation markers (KI67, 
PCNA), and hepatocyte markers (ABCC2, ALB, CYP3A4), 
and compared these with gene expression in cryopreserved 
hepatocytes and human liver tissue. As expected, stem cell 
markers and proliferation markers were highly expressed in 
all hydrogel conditions in both donors, whereas hepatocyte 
markers were low (Figure 3c).
2.4. Organoids in PIC can be Differentiated into Functional 
Hepatocyte-like Cells
It has previously been shown that human liver organoids can 
be differentiated toward hepatocyte-like cells when cultured 
in differentiation medium (DM), which contains N-[(3,5-dif-
luorophenyl)acetyl]-l-alanyl-2-phenyl]glycine-1,1-dimethylethyl 
ester (DAPT), fibroblast growth factor 19 (FGF19), dexametha-
sone and bone morphogenetic protein 7 (BMP-7), and is void 
of inducers of proliferation, such as Rspondin-1 and forskollin 
(FSK).[12,28] In order to compare the differentiation potential 
of human liver organoids cultured in PIC-LEC to Matrigel, 
we differentiated organoids toward hepatocyte-like cells. 
Light microscopy demonstrated that both Matrigel and PIC-
LEC organoids acquired a more dense and dark morphology 
at day 8 of differentiation compared to expansion conditions 
(Figure 4a). Analysis of the organoids by quantitative real-time 
PCR (qRT-PCR) after 8 days of differentiation confirmed that 
the stem cell marker LGR5 was downregulated in both hydro-
gels (Figure 4b). In contrast, several hepatocyte markers such 
as cytochrome p450 3A4 (CYP3A4), albumin (ALB), and mul-
tidrug resistance-associated protein 2 (MRP2) were upregu-
lated and reached comparable levels in PIC-LEC and Matrigel 
(Figure 4b).
We also assessed the functionality of the differentiated orga-
noids in both hydrogels with several assays. Important func-
tions of hepatocytes include the production of serum proteins, 
vectorial uptake, and secretion of several compounds, and urea 
cycle activity.[29] To determine the production of serum pro-
teins, we quantified the intracellular ALB concentration of the 
organoids at day 8 of differentiation. We measured comparable 
concentrations of ALB in PIC-LEC and Matrigel (Figure  4c). 
To determine vectorial transmembrane transport, we exposed 
organoids in both hydrogels to rhodamine123 (Rh123), a fluo-
rescent compound that is actively secreted from the apical 
membrane of hepatocytes by the transporter multidrug resist-
ance gene 1 (MDR1).[30] Organoids in both hydrogels accumu-
lated fluorescence inside their lumens (Figure 4d). To confirm 
that this accumulation was MDR1-specific, organoids were 
pretreated with the competitive MDR1 inhibitor verapamil. 
This resulted in an accumulation of Rh123 in the cytoplasm of 
the cells, whereas no fluorescence was observed in the lumen 
of the organoids, confirming the MDR1-specific transport of 
Rh123. Finally, we tested organoids in both hydrogels for their 
capacity to eliminate ammonium from the media, a measure 
for urea cycle activity. Ammonia reacts with α- ketoglutaric acid 
to form l-glutamate, which is catalyzed by l-glutamate dehydro-
genase (GLDH).[31] The intracellular concentration of GLDH 
was comparable in organoids from both hydrogels (Figure 4e), 
along with ammonia elimination from the media (Figure 4f).
2.5. Long-Term Expansion of Organoids in PIC
One of the main advantages of organoid cultures is that they 
can be serially passaged, allowing for seemingly unlimited 
expansion. This continued expansion is fueled by the LGR5+ 
stem cells in liver organoid cultures.[32] In order to test if this 
stem cell phenotype and organoid proliferation capacity can be 
retained in PIC-LEC over several passages, we cultured human 
liver organoids from two donors for 14 passages with weekly 
passaging. Light microscopy images confirmed that the orga-
noids retained their cystic morphology through all passages 
and remained highly comparable in PIC-LEC and Matrigel 
(Figure 5a). qRT-PCR showed that the expression of LGR5 in 
organoids cultured in PIC-LEC or Matrigel was stable over the 
course of 14 weeks (4 months) (Figure  5b). We then assessed 
the differentiation potential of organoids that had been cultured 
in PIC-LEC for 2, 6, and 10 passages (P2, P6, and P10). After 
those passages in EM, in either PIC-LEC or Matrigel, organoids 
from two donors were differentiated in DM for 8 days and sub-
sequently analyzed by mRNA sequencing (P6) and qRT-PCR 
(P2, P6, and P10).
At P6, the 100 most significant differentially-expressed genes 
in DM versus EM displayed an identical pattern in PIC-LEC 
compared to Matrigel (Figure  5c). Gene ontology analysis[33] 
of these genes revealed significant enrichment for processes 
related to liver functions, such as lipid and alcohol metabolism 
(Tables S1 and S2, Supporting Information). Analysis by qRT-
PCR confirmed that the gene expression of several hepatocyte 
markers in differentiated organoids was upregulated compared 
to their respective EM controls in all hydrogels and that this 
upregulation was reproducible at P2, P6, and P10 (Figure 5d), 
indicating that organoids retain their differentiation potential 
over several passages in PIC-LEC.
2.6. Human Recombinant Laminin-111 Can Substitute LEC
The hydrogel we have developed and extensively characterized 
for human liver organoid culture contains a chemically well-
defined PIC component supplemented by a bioactive LEC, 
and the combination has several advantages over Matrigel. 
However, the LEC originates from mouse sarcoma and is thus 
not xenofree and not suitable for clinical applications. There-
fore, we examined the possibility of using human recombinant 
laminin-111 (hrlaminin-111) as a substitute for LEC. The experi-
ments with LEC showed a concentration-dependent prolifera-
tion of organoids in LEC at concentrations of 1, 2, and 3 mg mL−1 
(Figure 1c). We prepared PIC hydrogels with the same concen-
trations of hrlaminin-111 and seeded single organoid cells in 
those gels. For two of the three analyzed donors, we observed a 
comparable concentration-dependent proliferation in the PIC-
LEC and PIC-hrlaminin-111 (Figure  6a). For the third donor 
however, proliferation in the PIC-hrlaminin-111 seemed lower 
compared to PIC-LEC (Figure S2, Supporting Information). 
To further characterize the phenotype and proliferative poten-
tial of organoids cultured in PIC-LEC and  PIC-hrlaminin-111, 
we conducted immunofluorescent stainings for ECAD, keratin 
19 (K19), Ki67, and PCNA, which confirmed that the cells in 
all hydrogels retained an epithelial ECAD- positive phenotype 
Adv. Funct. Mater. 2020, 2000893
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and were highly proliferative (Figure  6b). These data indicate 
that, although less efficient, it seems possible to replace LEC 
by hrlaminin-111 and possibly other human recombinant ECM 
proteins as the bioactive components in PIC, rendering the PIC 
completely synthetic and applicable for clinical applications 
such as cell therapy or tissue engineering.
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Figure 4. Organoids differentiated into functional hepatocyte-like cells in PIC. Organoids were differentiated in Matrigel, 1k PIC-LEC, or 5k PIC-LEC 
for 8 days (N = 4). a) Light microscopy images of organoids showing that differentiated organoids became denser and darker compared to EM 
organoids in all hydrogels. b) Gene expression of stem cell and hepatocyte markers in differentiated organoids from four independent donors. 
Transcriptional levels of leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), albumin (ALB), cytochrome p450 3A4 (CYP3A4), and 
multidrug resistance-associated protein 2 (MRP2) were determined by qRT-PCR and compared to cryopreserved human hepatocytes. Hepatocyte 
functionality of differentiated organoids in the different hydrogels was assessed. Four different donors were analyzed in independent experiments. 
d) Rh123 transport was determined as read-out for MDR1 activity. Verapamil was added as an inhibitor of MDR1 function. c) Albumin concentra-
tions and e) GLDH levels in cell lysates were measured after incubation in DM for 24 h. Comparison was normalized to total protein concentra-
tions. Graphs indicate mean ± SD. f) Ammonium elimination from the culture medium was determined as read-out for hepatocyte functionality. 
*indicates p-value ≤ 0.05.
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Figure 5. Long-term expansion of organoids in PIC. Organoids from two different donors were cultured for 12 weeks in Matrigel, 1k PIC-LEC, and 5k 
PIC-LEC with weekly passaging. a) Light microscopy pictures show that organoids maintained their morphological phenotype during all passages in 
Matrigel, 1k PIC-LEC, and 5k PIC-LEC. b) qRT-PCR analysis of the stem cell marker LGR5 shows stable expression levels at passage 2, 6, 10, and 14 
in all different hydrogels. c) mRNA sequencing on organoids from two independent donors in EM and after differentiation (day 8 in DM). The 100 
most significant differentially-expressed genes in DM versus EM are displayed in a heatmap. Note that EM samples from both donors and all three 
hydrogels show a very similar expression pattern and that all DM samples from both donors and all three different hydrogels are similar. A full list of 
genes is provided as Table S1, Supporting Information. d) Gene expression of hepatocyte markers in differentiated organoids from two independent 
donors during long-term culture in Matrigel or PIC hydrogels. Transcriptional levels of hepatocyte markers ALB, CYP3A4, and MRP2 were determined 
by qRT-PCR and compared to their respective EM controls (N = 2).
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3. Conclusion
In this study, we developed and characterized a novel synthetic 
hydrogel for the expansion and differentiation of human adult 
stem cell-derived liver organoids. PIC hydrogel alone was 
not sufficient to support organoid growth, but PIC mixed with 
LEC supported organoid formation and proliferation (Figure 1). 
As no covalent reaction can occur between PIC and LEC in the 
absence of catalysts, the interaction of PIC and LEC is most 
probably non-covalent self-assembly, but the exact interaction 
of PIC and LEC remains to be determined. The optimized 
PIC-LEC hydrogel supported organoid proliferation at rates 
that were similar to Matrigel (Figure 1), with lower stiffnesses 
most favorable for organoid proliferation. We showed that the 
organoids were highly proliferative in PIC-LEC when cultured 
in EM (Figure 3) and could be efficiently differentiated toward 
functional hepatocyte-like cells when cultured in DM (Figure 4). 
Importantly, the stem cell phenotype and proliferation and dif-
ferentiation capacity of the organoids could be maintained in 
PIC-LEC over several passages, enabling their seemingly unlim-
ited expansion and subsequent maturation (Figure  5). Finally, 
we showed that the LEC in the PIC-LEC gels could be replaced 
by hrlaminin-111, resulting in a completely synthetic hydrogel 
for the expansion of human liver organoids. Future studies will 
have to confirm the suitability of this synthetic hydrogel for dif-
ferentiation of human liver organoids toward hepatocytes and 
cholangiocytes. Moreover, hrlaminin-111 might be replaced 
or complemented by other ECM components to improve the 
differentiation to either hepatocytes or cholangiocytes.[34] It 
will also be interesting to replace full-length ECM proteins by 
Adv. Funct. Mater. 2020, 2000893
Figure 6. Human recombinant laminin-111 can substitute LEC. a) Organoids from three different donors were cultured for 7 days in Matrigel, PIC-plain, 
or 1k PIC supplemented with either LEC or human recombinant Laminin (hrlaminin-111). Light microscopy pictures show a similar morphological phe-
notype in LEC and hrlaminin-111, with increased organoid size and number at higher laminin concentrations. (N = 3) b) Immunofluorescent analysis of 
paraffin-embedded organoids confirmed that the organoids in all gels have an epithelial progenitor phenotype and are highly proliferative. Organoids 
cultured in Matrigel, 5k PIC with 3 mg mL−1 LEC or 5k PIC with 2 mg mL−1 hrlaminin-111 are displayed. Human liver tissue was used as a control (N = 1).
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 peptides derived from laminin-111 and other ECM components. 
For PEG hydrogels, it has been shown that high concentrations 
of covalently-linked A55 peptide (GGFLKYTVSYDI) and AG73 
peptide (RKRLQVQLSIRT), which are both located on the α-1 
laminin chain, supported intestinal organoid proliferation and 
survival that approached levels in Matrigel.[20]
Together with the recent preprint by Sorrentino et al., this is 
the first chemically-defined and synthetic hydrogel that supports 
human liver organoid expansion and differentiation at rates 
comparable to Matrigel.[21] Both hydrogels, PEG-based and PIC-
based, have their own advantages. An enzymatically or chemi-
cally crosslinked PEG hydrogel was the first synthetic hydrogel 
applied for intestinal organoid culture derived from multi-
potent or PSCs.[20,35] ECM components such as fibronectin, 
laminin-111, collagen IV, hyaluronic acid, and perlecan were 
added to the hydrogel, and a minimized PEG-RGD hydrogel 
was sufficient to support organoid formation and proliferation. 
This hydrogel system was recently adapted to liver organoids.[21] 
Proliferation rates of intestinal or liver organoids in the PEG 
hydrogels were not quantified however, so it remains to be 
determined how they compare to our PIC hydrogel. In a very 
elegant approach, the authors also modified the PEG hydrogels 
to be hydrolytically or protease-degradable, as such mimicking 
the dynamic character of the in vivo environment.[20,35] Similar 
modifications may be applied to the PIC hydrogels by applying 
a copper-free click chemistry as previously published.[36] The 
most striking difference between the PEG and PIC hydrogels 
is the mode of gelation. Whereas the chemically- or enzymat-
ically-crosslinked PEG hydrogel is advantageous for applica-
tions where a controlled stiffness over a prolonged period of 
time is necessary, the thermoreversible properties of the PIC 
hydrogel allow for easier cell recovery during organoid culture 
and make it advantageous for certain practical purposes such 
as bioprinting and in vivo cell therapy.[37] PEG-based hydrogels 
have already been applied as delivery vehicles in vivo, where 
they supported localized engraftment of human intestinal 
organoids derived from PSCs in colonic mucosal wounds and 
enhanced wound closure.[35] In order to facilitate gelation in 
situ, a custom made-device was applied, in which the hydrogel 
precursor solution and the crosslinking solution only met in 
the tubing during injection.[35] PIC hydrogels have also been 
applied in vivo for wound healing studies and subcutaneous 
cell transplantations without causing any adverse effects.[26,27] 
The thermo-responsive properties of the PIC hydrogels made 
in vivo applications very convenient, and the PIC gelated within 
1 min upon contact with the warm skin.[27] These results high-
light the great potential for in vivo applications of organoids cul-
tured in PIC. Of note, we recently published a protocol for the 
large-scale expansion of human liver organoids in suspension 
culture,[28] and foresee that a combination of this large-scale 
expansion method and our well-defined synthetic hydrogel will 
pave the way for clinical applications of human liver organoids 
in the near future.[38]
4. Experimental Section
Hydrogel Preparation and Characterization: Noviogel (PIC) was 
purchased from Sopachem (1k-PIC-P, 1k-PIC-RGD, 5k-PIC-P, and 
5k-PIC-RGD, followed by catalog numbers: NCN01, NCN03, NCN02, 
and NCN04, respectively). Stock solutions of 5  mg mL−1 were made 
by adding 3 mL of advanced DMEM/F12 (AD, Gibco) to each bottle of 
PIC. To optimize the PIC hydrogels, both 1k and 5k PIC were tested in 
three concentrations: 1, 1.75, and 2.5  mg mL−1. Where indicated, LEC 
(Corning) was added to each PIC formulation at concentrations of 1, 
2, or 3 mg mL−1 to test the dose effects. When LEC was replaced with 
human recombinant laminin-111 (hrlaminin-111, Biolamina, LN111-050) 
the same concentrations were used (1, 2, or 3 mg mL−1).
Working Solutions of Thermoresponsive Materials: PIC, LEC, and 
Matrigel (Corning, 356 237) were divided into aliquots to reduce 
frequent freeze-thaw cycles and stored at −20  °C. To make hydrogels, 
materials were thawed and prepared on ice before gelation. Once plated, 
hydrogels were allowed to solidify for 15–30 min at 37 °C.
Rheological measurements were conducted on a discovery HR-2 
rheometer (TA instruments) to test the mechanical properties of 
hydrogels made from PIC, PIC-LEC, or Matrigel. A temperature-
controlled plate (20  mm parallel plate, aluminium-105381) was used 
for all measurements. Settings included a geometry diameter of 20 mm 
and a measuring gap of 200 µm. For hydrogel formation measurements, 
150  µL of each hydrogel premix was deposited onto the plate and 
conditioned for 2 min at 4  °C. The plate was then heated (strain 1%, 
angular frequency 1.0 rad s−1) from 4 to 37 °C at a speed of 7 °C min−1, 
and then continuously measured at 37 °C for another 10 min. Following 
the hydrogel formation step, frequency sweep tests were carried out and 
data was collected in the frequency range of 10 rad s−1 to 0.1 rad s−1. For 
thermoreversible characterization, hydrogel formation was carried out 
as described above. After remaining at 37 °C for 10 min, the plate was 
cooled from 37 to 4 °C at a rate of 7 °C min−1. When the temperature of 
the plate reached 4 °C, it was held for another 10 min to observe if the 
hydrogels could become fluidic again.
Human Liver Organoid Establishment: Liver biopsies were obtained 
during liver transplantation at the Erasmus Medical Center Rotterdam 
and in accordance with the ethical standard of the Helsinki Declaration 
of 1975. Use of the tissue for research purposes was approved by the 
Medical Ethical Council of the Erasmus Medical Center and informed 
consent by the liver transplant recipient was given (MEC-2014-060). To 
establish human liver organoid lines, liver biopsies were cut into small 
pieces, followed by the enzymatic digestion with type II collagenase 
(0.125 mg mL−1, Gibco) and dispase (0.125 mg mL−1, Gibco) in DMEM 
GlutaMAX (Gibco) containing 1% fetal calf serum (FCS, Gibco). The 
supernatant was collected every hour. Tissue digestion followed by 
supernatant collection was performed three times. Collected single cells 
were washed in DMEM GlutaMAX (Gibco) containing 1% FCS (Gibco) 
and centrifuged for 5 min at 1500  rpm. The cells were resuspended in 
Matrigel (Corning) at a concentration of ≈400 cells per µL. Cells were 
seeded in droplets (50  µL) in non-attaching 24-well plates (M9312, 
Greiner, Merck). EM was added after ≈15  min incubation at 37  °C, 
5% CO2.
Organoid Expansion and Differentiation in PIC and Matrigel Droplets: 
For human liver organoid expansion, previously defined EM was 
used.[9] EM was based on advanced DMEM/F12 (AD, Gibco) containing 
1% GlutaMax (Gibco), HEPES (10  mm, Gibco), and 1% penicillin-
streptomycin (Gibco, Dublin, Ireland). EM was supplemented with 
10% Rspondin-1 conditioned medium (the Rspo1-Fc-expressing cell line 
was kindly provided by Calvin J. Kuo), 1% N2 supplement (Invitrogen), 
2% B27 supplement without vitamin A (Invitrogen), N-acetylcysteine 
(1.25  mm, Sigma-Aldrich), nicotinamide (10  mm, Sigma-Aldrich), 
epidermal growth factor (50  ng mL−1, EGF, Invitrogen), hepatocyte 
growth factor (25 ng mL−1, HGF, Peprotech), fibroblast growth factor 10 
(0.1  µg mL−1, FGF10, Peprotech), recombinant human (Leu15)-gastrin 
I (GAS, 10  nM, Sigma-Aldrich), FSK (10 µM, FSK), and A83-01 (5 µM, 
Tocris Bioscience).
During the optimization of PIC hydrogels, single cells were prepared 
from organoids by trypsinizing with TrypLE Express Enzyme (12604-013, 
Gibco). Single cells were seeded in droplets (50 µL) at a concentration 
of 300–1000 cells per µL, in temperature and humidity-balanced 24-well 
plates (M9312, Greiner, Merck). After seeding, plates were incubated at 
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37  °C for 15–30  min to facilitate hydrogel gelation and thereafter, EM 
(500 µL) containing Y-27632 (10 µM, SelleckChem) was added to each 
well. After three days of culture, Y-27632 (SelleckChem) was no longer 
used. Medium was refreshed every 2–3 days; organoids were passaged 
weekly at a 1:3–1:4 split ratio by mechanical dissociation method. All 
cultures were incubated at 37 °C, 5% CO2.
For liver organoid differentiation, previously-defined differentiation 
medium (DM) was used. DM was based on advanced DMEM/F12 
(AD, Gibco) containing 1% GlutaMax (Gibco), HEPES (10 mm, Gibco), 
and 1% penicillin-streptomycin (Gibco), and supplemented with 
1% N2 supplement (Invitrogen), 2% B27 supplement without vitamin 
A (Invitrogen), N-acetylcysteine (1.25  mm, Sigma-Aldrich), EGF 
(50 ng mL−1, Invitrogen), HGF (25  ng mL−1, Peprotech), FGF19 
(100 ng mL−1, FGF19, Peprotech), recombinant human GAS (10  nM, 
Sigma-Aldrich), A83-01 (500 nM, Tocris Bioscience), BMP-7 (25 ng mL−1, 
Peprotech), 30 µM dexamethasone (Sigma-Aldrich), and DAPT (10 µM, 
Selleckchem). Prior to switching to DM from EM, liver organoids were 
primed in EM containing BMP-7 (25  ng mL−1, Peprotech) for three 
days. Medium was then switched to DM. Medium was refreshed every 
2–3 days for 8 days.
Measurement of Cell Proliferation: ABA was used to measure the cell 
proliferation. For ABA, the stock solution (Dal1100, Life Technologies 
Europe BV) was diluted 1:10 in DMEM/F12 without phenol red (21 041, 
Gibco), sterilized through a 0.22  µm filter, and pre-warmed to 37  °C. 
EM was removed from each well and replaced with pre-warmed ABA 
solution. Organoids were incubated in ABA solution for 90 min at 37 °C, 
5% CO2. After incubation, ABA solution was transferred to a new 24-well 
plate (Greiner) after which, fresh pre-warmed EM was added to the old 
plate. For ABA measurement, Fluoroskan Ascent FL (Thermo Fisher 
Scientific) was used. The wavelength of excitation and emission were 544 
and 577 nm, respectively. ABAs were conducted on days 0, 1, 4, and 7 after 
single-cell seeding. Data analysis was normalized to day 0; results were 
graphed as fold-changes using GraphPad Prism (GraphPad Software).
Cryopreserved Hepatocyte Culture: LiverPool Cryoplateable 
Hepatocytes (10-donor, mixed gender) were provided by Bioreclamation 
IVT. Hepatocytes were cultured in a collagen sandwich according to the 
manufacturer’s instructions, and supplemented with the recommended 
InVitroGRO CP media (Bioreclamation IVT). For mRNA sequencing, 
hepatocytes were harvested after 4 h of sandwich culture.
RNA Isolation and qRT-PCR: The RNeasy Mini Kit (Qiagen, Hilden, 
Germany) was used to isolate RNA from tissues, hepatocytes, and 
organoids following the manufacturer’s instructions. RNA quality and 
quantity was measured with DS-11 spectrophotometer (DeNovix). 
Complementary DNA (cDNA) was synthesized with the iScript cDNA 
synthesis kit (Bio-Rad) following the manufacturer’s instructions. 
qRT-PCR was used to determine relative expression of target genes 
using validated primers (Table S3, Supporting Information) using the 
SYBR Green method (Bio-Rad). Normalization was carried out using 
reference genes Hypoxanthine-guanine phosphoribosyltransferase and 
ribosomal protein L19.
Rhodamine123 Transport Assay: Liver organoids were differentiated 
in PIC-LEC or Matrigel droplets for 8 days as previously described. For 
Rh123 transport assays, organoids were pretreated with DM containing 
verapamil (10  µM, Sigma-Aldrich) or DMSO for 30  min. Organoids 
were then removed from PIC-LEC or Matrigel and resuspended in DM 
containing rh123 (100  µM, Sigma-Aldrich) and incubated at 37  °C for 
10 min. Fluorescence was visualized by an EVOS FL cell imaging system 
(Life Technologies).
Ammonium Elimination Assay: For ammonium elimination assays, 
liver organoids were differentiated in PIC-LEC or Matrigel droplets for 
8 days as previously described. Organoids were incubated with DM 
supplemented with NH4Cl (2 mm) for 24 h. After 24 h, media samples 
were harvested and stored at −20 °C. Afterward, Tryple-Express (Gibco) 
was added to each well and organoids were trypsinized for cell counting. 
Cell counts were carried out using the TC20 automated cell counter 
(Bio-Rad). Viable cells were determined using trypan blue exclusion 
assay. Ammonium concentrations were measured with the urea/
ammonia Assay Kit (Megazyme). As a control, DM containing NH4Cl 
(2 mm) was incubated for 24 h without cells. Ammonia elimination rates 
were normalized to live cell numbers.
GLDH Expression and Albumin Production: To quantify the intracellular 
levels of GLDH and ALB, liver organoids were differentiated in PIC-LEC 
or Matrigel droplets for 8 days, as previously described. Organoids were 
provided with fresh DM 24 h before being lysed in MilliQ water. GLDH 
and ALB were measured in the cell lysates using a DxC-600 Beckman 
chemistry analyzer (Beckman Coulter). Values were normalized to total 
protein concentrations.
Microscopy and Immunofluorescence Analysis: Imaging of the 
organoids was performed using an EVOS FL cell imaging system (Life 
Technologies) and an Olympus BX51 microscope in combination with 
an Olympus DP73 camera. Detailed information of applied antigen 
retrieval methods, antibodies, dilutions, and incubation times are listed 
in Table S4, Supporting Information.
Bright field images were taken to track organoid morphology 
throughout expansion in different hydrogel formulations. Images were 
also taken to compare the morphology of organoids in EM and DM.
For immunofluorescent (IF) staining, organoids were fixed with 4% 
neutral buffered formalin containing 0.1% eosin and incubated at 37 °C 
overnight. Fixed samples were dehydrated and embedded in paraffin or 
stored in 70% ethanol at 4  °C for up to 1 month; 4 µm thick paraffin 
sections were prepared for IF staining. To start the IF staining procedure, 
the paraffin sections were first heated at 62 °C for 15 min and dewaxed by 
xylene, followed by rehydration in gradient ethanol concentrations from 
100% to 70%. Then, sample sections were incubated in antigen retrieval 
solution for 30  min at 98  °C. After balancing to room temperature, 
sample sections were treated with NH4Cl solution (20 mm) for 10 min to 
reduce background autofluorescence and blocked with 10% goat serum 
for 1 h to avoid non-specific antibody binding. Next, primary antibodies 
against ECAD, Ki67, PCNA, and K19 were added to the sections and 
incubated overnight at 4 °C. After being washed with tris-buffered saline 
containing Tween 20 three times, sample sections were incubated with 
secondary antibodies (5 µM), including mouse anti-rabbit Alexa Fluor 
488 (Molecular Probes), mouse anti-rabbit Alexa Fluor647 (Molecular 
Probes), rabbit anti-mouse Alexa Fluor488 (Molecular Probes), and 
rabbit anti-mouse Alexa Fluor647 (Molecular Probes). Nuclei were 
stained with DAPI (0.5 µg mL−1, Sigma Aldrich).
Whole Transcriptome Sequencing and Analysis: For whole transcriptome 
sequencing, RNA was isolated from organoids using the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’s instructions. Library 
preparation, 75  bp single-end sequencing on Illumina NextSeq500 
(Illumina) and mapping raw reads was performed as previously 
described.[39] The raw files have been uploaded to Gene Expression 
Omnibus under the accession GSE143223. Data was merged 
with previously sequenced LiverPool Cryoplateable Hepatocytes 
(GSE123498)[28] and normalized. Differentially-expressed genes were 
identified using the DESeq2 package with standard settings.[40] Human 
liver tissue whole transcriptome sequencing data (Liver_FASEB) was 
obtained from an online database.[41] Heatmaps were generated using 
gplots. ToppFun was used for functional enrichment analysis based on 
functional annotations and protein interactions networks.[33]
Human Recombinant Laminin-111 Condensation: To obtain high-
concentration human recombinant laminin-111 (hrlaminin-111), 
commercial hrlaminin-111 (Biolamina) was condensed with an 
Amicon Ultra-0.5 centrifugal filter unit (Millipore, Merck) following 
the manufacturer’s instructions. hrlaminin-111 was concentrated from 
100 µg mL−1 to ≈5  mg mL−1, as measured by BCA assay with a Pierce 
BCA protein assay kit (Thermo Scientific). Afterward, the condensed 
hrlaminin-111 replaced LEC to make a chemically-defined PIC hydrogel 
for liver organoid culture.
Statistical Analyses: ABA results (Figure  1d,e) and rheological 
results (Figure  2) were analyzed in an Excel datasheet and converted 
into graphs using Graphpad Prism 8. qRT-PCR results (Figures  4b 
and  5b), ALB secretion (Figure  4c), GLDH expression (Figure  4e), 
and ammonium elimination (Figure  4f) were analyzed using a Tukey’s 
multiple comparisons test by two-way ANON multiple comparisons. 
The p-values are indicated in the respective figures.
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Data Availability: The whole transcriptome sequencing datasets 
generated and analyzed during this study are available in the Gene 
Expression Omnibus repository under the accession GSE143223. Other 
datasets generated and analyzed during the current study are available 
from the corresponding author upon request.
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